Biotech · Private company
Oncovir, Inc.
Track this companyFree. Adds Oncovir, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials146 recruiting or active
Pipeline programs4From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline4
- HiltonolPhase 2 · MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- Poly-ICLC combination treatment with aPD-1 (Nivolumab or Pembrolizumab) or aPD-L1 (Atezolizumab or Durvalumab) over 6 monthsPhase 2 · Solid CancerClinicalTrials.gov · fetched Nov 12, 2026
- Expansion CohortPhase 1 · Malignant Pleural MesotheliomaClinicalTrials.gov · fetched Nov 12, 2026
- SafetyPhase 1 · Malignant Pleural MesotheliomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials14
- Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic CancerPHASE1_PHASE2 · RECRUITING · started May 27, 2025ClinicalTrials.gov NCT06782932 · fetched Nov 12, 2026
- Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLCPHASE1_PHASE2 · RECRUITING · started May 13, 2024ClinicalTrials.gov NCT05950139 · fetched Nov 12, 2026
- Intratumoral and Systemic Hiltonol® (Poly-ICLC) in Prostate Cancer Patients on Active SurveillancePHASE2 · RECRUITING · started Jan 16, 2024ClinicalTrials.gov NCT06343077 · fetched Nov 12, 2026
- A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.PHASE1 · RECRUITING · started Aug 18, 2021ClinicalTrials.gov NCT03219450 · fetched Nov 12, 2026
- Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural MesotheliomaPHASE1 · COMPLETED · started Aug 19, 2020ClinicalTrials.gov NCT04525859 · fetched Nov 12, 2026
- Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent GlioblastomaPHASE1 · COMPLETED · started Jan 8, 2020ClinicalTrials.gov NCT04201873 · fetched Nov 12, 2026
- Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel CombinationsPHASE1 · COMPLETED · started Jun 21, 2019ClinicalTrials.gov NCT03835533 · fetched Nov 12, 2026
- NeoVax Plus Ipilimumab in Renal Cell CarcinomaPHASE1 · ACTIVE_NOT_RECRUITING · started Mar 3, 2019ClinicalTrials.gov NCT02950766 · fetched Nov 12, 2026
- Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1PHASE1_PHASE2 · TERMINATED · started Sep 25, 2018ClinicalTrials.gov NCT03721679 · fetched Nov 12, 2026
- Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat GlioblastomaPHASE1 · ACTIVE_NOT_RECRUITING · started Mar 1, 2018ClinicalTrials.gov NCT03223103 · fetched Nov 12, 2026
- Pembrolizumab + Poly-ICLC in MRP Colon CancerPHASE1_PHASE2 · COMPLETED · started Jan 10, 2018ClinicalTrials.gov NCT02834052 · fetched Nov 12, 2026
- Neoadjuvant Hiltonol® (PolyICLC) for Prostate CancerPHASE1 · COMPLETED · started Jun 16, 2017ClinicalTrials.gov NCT03262103 · fetched Nov 12, 2026
- A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma RecurrencePHASE2 · COMPLETED · started Jul 1, 2015ClinicalTrials.gov NCT02334735 · fetched Nov 12, 2026
- In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®PHASE2 · COMPLETED · started Mar 1, 2015ClinicalTrials.gov NCT02423863 · fetched Nov 12, 2026